Latest News
FDA approves Sanofi's subcutaneous Sarclisa Escena as first anticancer therapy delivered via on-body injector
10 July 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the US Food and Drug Administration (FDA) has approved the company's subcutaneous Sarclisa (isatuximab-irfc) Escena for use in combin...
Nexstim expands Health Canada approval for NBS 6
10 July 2026 - Finland-based medical technology company Nexstim Plc (FN HEL:NXTMH) said on Friday that it has received Health Canada approval to expand the approved indications for its NBS 6 system to include diagnostic applications and the treatment...
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
10 July 2026 - Accord BioPharma, the US specialty division of India-based Intas Pharmaceuticals Ltd, focused on the development of oncology, immunology, and central nervous system (CNS) therapies, announced on Thursday that the US Food and Drug Admin...
Biohaven announces scientific leadership changes
10 July 2026 - Biopharmaceutical company Biohaven Ltd (NYSE:BHVN) announced on Wednesday scientific leadership role transitions designed to accelerate drug innovation and external collaborations.David Pirman, Ph.D., has been promoted to executive vic...
Labcorp declares quarterly dividend of USD0.72 per share
10 July 2026 - Laboratory services provider Labcorp Holdings Inc (NYSE:LH) announced on Thursday that its board of directors has declared a cash dividend of USD0.72 per share of common stock.This amount is unchanged from the previous quarterly divide...